Who
John B. Ketchum
Director
Company insider
Files Form 4 as: Director, Tango Therapeutics.
In numbers
- Trades disclosed
- 10
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 29 Aug 2023
- Last trade
- 5 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 8 Jun 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,000 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —6,250 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,125 at $0.00 | filing |
| 5 Jun 2024filed 7 Jun 2024 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,687 at $0.00 | filing |
| 29 Aug 2023filed 31 Aug 2023 | TNGX Tango Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 29 Aug 2023filed 31 Aug 2023 | TNGX Tango TherapeuticsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.